These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18193641)

  • 1. Diseases associated with altered ryanodine receptor activity.
    Durham WJ; Wehrens XH; Sood S; Hamilton SL
    Subcell Biochem; 2007; 45():273-321. PubMed ID: 18193641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.
    Priori SG; Napolitano C
    J Clin Invest; 2005 Aug; 115(8):2033-8. PubMed ID: 16075044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ryanodine receptor channelopathies.
    Betzenhauser MJ; Marks AR
    Pflugers Arch; 2010 Jul; 460(2):467-80. PubMed ID: 20179962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex].
    Lunardi J; Monnier N
    Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S70-7. PubMed ID: 15269663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ryanodine receptor channelopathies.
    Benkusky NA; Farrell EF; Valdivia HH
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1280-5. PubMed ID: 15336975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.
    Murayama T; Kurebayashi N; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    PLoS One; 2015; 10(6):e0130606. PubMed ID: 26115329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ryanodine receptor physiology and its role in disease.
    Lanner JT
    Adv Exp Med Biol; 2012; 740():217-34. PubMed ID: 22453944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.
    Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM
    J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ryanodine receptor: a pivotal Ca2+ regulatory protein and potential therapeutic drug target.
    Dulhunty AF; Casarotto MG; Beard NA
    Curr Drug Targets; 2011 May; 12(5):709-23. PubMed ID: 21291389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
    Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
    Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
    [No Abstract]   [Full Text] [Related]  

  • 14. Core myopathies and malignant hyperthermia susceptibility: a review.
    Brislin RP; Theroux MC
    Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in RYR1 in malignant hyperthermia and central core disease.
    Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
    Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor.
    Avila G; Dirksen RT
    J Gen Physiol; 2001 Sep; 118(3):277-90. PubMed ID: 11524458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of ion-regulatory membrane proteins of excitation-contraction coupling and relaxation in inherited muscle diseases.
    Froemming GR; Ohlendieck K
    Front Biosci; 2001 Jan; 6():D65-74. PubMed ID: 11145921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmia pathogenesis.
    Scoote M; Williams AJ
    Cardiovasc Res; 2002 Dec; 56(3):359-72. PubMed ID: 12445877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
    Lyfenko AD; Goonasekera SA; Dirksen RT
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders.
    Treves S; Anderson AA; Ducreux S; Divet A; Bleunven C; Grasso C; Paesante S; Zorzato F
    Neuromuscul Disord; 2005 Oct; 15(9-10):577-87. PubMed ID: 16084090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.